Skip to content
Clinical Trials – home
Not yet recruiting

Durvalumab with chemotherapy drug combination versus surveillance in patients with low‑risk localized stomach or gastroesophageal junction cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on patients with low‑risk, localized, non‑metastatic gastric adenocarcinoma that arises at the stomach or the junction where the stomach meets the esophagus. After surgery, the usual adjuvant approach is a combination of chemotherapy drugs given intravenous: docetaxel, oxaliplatin, fluorouracil together with calcium folinate, followed by the immune‑modulating agent durvalumab.

The purpose of the trial is to compare the standard post‑operative regimen with a de‑escalation strategy that uses only careful monitoring (surveillance) after surgery. Participants are randomly assigned to receive either the full chemotherapy and immunotherapy schedule, administered through a vein in a series of treatment cycles, or to enter the surveillance arm where no additional cancer‑directed drugs are given, but regular check‑ups are performed.

All participants will attend scheduled clinic visits for blood tests, imaging and physical examinations over a period of up to two years to assess whether the cancer returns and to record any side effects. The study collects this information to determine which approach provides the best balance of disease‑free survival and safety.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization to Treatment Group

    You will be assigned by the study to either the standard treatment arm or the de‑escalation (surveillance) arm.

    The assignment is made randomly and you will be informed of the group to which you belong.

  2. Step 2

    Standard Treatment – Begin D‑FLOT Chemotherapy

    If you are in the standard arm, you will start a chemotherapy regimen called D‑FLOT.

    The regimen includes four medicines given by intravenous (IV) infusion or injection:

    Docetaxel: 50 mg per square meter of body surface area (mg/m²) given as an IV injection.

    Oxaliplatin: 85 mg/m² given as an IV infusion.

    Fluorouracil: 2600 mg/m² given as an IV infusion.

    Calcium folinate: 200 mg/m² given as an IV infusion.

    Each drug is administered on the day specified by the study protocol, typically in a single treatment cycle.

    The cycle is repeated according to the schedule defined in the protocol.

  3. Step 3

    Standard Treatment – Receive Durvalumab

    After completing the D‑FLOT chemotherapy cycles, you will receive the immunotherapy drug durvalumab.

    The dose is 1500 mg given as an IV infusion.

    Durvalumab is administered repeatedly as outlined in the study protocol.

  4. Step 2

    De‑escalation Arm – Surveillance Only

    If you are assigned to the de‑escalation arm, you will not receive chemotherapy or durvalumab.

    You will enter a surveillance schedule that includes regular check‑ups to monitor your health.

  5. Step 4

    Follow‑Up Visits and Monitoring

    All participants, regardless of the assigned arm, will attend follow‑up visits according to the study timetable.

    During these visits, doctors will perform examinations and tests to assess disease‑free survival.

    The follow‑up period continues for at least two years after the start of treatment or surveillance.

Who can join the trial?

13 criteria

  • Be at least 18 years old.
  • Have a diagnosis of non‑metastatic (cancer that has not spread) gastric or gastro‑esophageal junction adenocarcinoma, confirmed by tissue testing.
  • Have completed pre‑operative chemotherapy with the D‑FLOT regimen (a combination of fluoropyrimidine, platinum drugs, and durvalumab) and undergone surgery that removed all visible tumor with clean margins, known as an R0 resection.
  • Be considered low risk for cancer returning, meaning no cancer was found in the lymph nodes (ypN0) after surgery and the tumor stage is ypT0‑3, with at least 16 (or 7) lymph nodes examined according to guidelines.
  • Have an ECOG Performance Status of 0‑1, which means you can carry out normal daily activities with little or no limitation.
  • Be medically fit to receive additional chemotherapy after surgery.
  • Show adequate organ function (normal liver, kidney, blood counts, etc.) as defined in the study protocol.
  • Have no medical condition that would prevent you from completing the study’s tests or procedures.
  • Have a negative post‑operative ctDNA test (no detectable cancer DNA in the blood).
  • Agree to provide a blood sample for whole‑genome sequencing (WGS) so a personalized ctDNA test can be designed, using any available tumor tissue.
  • Sign and date an informed consent form.
  • Have health insurance or equivalent coverage.
  • Be randomized within 10 weeks after surgery (the time between surgery and randomization cannot be longer than 10 weeks).

Who cannot join the trial?

9 criteria

  • Contraindication to postoperative treatment (D‑FLOT) – meaning a medical reason that makes it unsafe for you to receive the standard chemotherapy regimen after surgery (the drugs durvalumab, 5‑fluorouracil, oxaliplatin, and docetaxel).
  • Receiving other chemotherapy or experimental cancer drugs at the same time – you cannot be on any other cancer treatment while participating.
  • Being enrolled in another clinical study – unless that other study only observes patients and does not give any treatment.
  • Inability to understand French – you must be able to read and understand the study information in French.
  • Suspected serious infection – any sign that you might have a serious infection at the time of enrollment.
  • Pregnant or breastfeeding – women who are pregnant or nursing a baby cannot join the trial.
  • Under legal guardianship, tutorship, or deprived of liberty – individuals who are not legally able to give consent because of a court‑appointed guardian or are incarcerated.
  • Having esophageal squamous cell carcinoma or esophageal adenocarcinoma – the trial is only for gastric or gastro‑esophageal junction cancer, not for cancers that start in the esophagus.
  • Persistent moderate or worse side effects from previous treatment (grade > 1 toxicity) – ongoing side effects that are more than mild (grade 1) from prior therapy prevent participation.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Durvalumab

    is a medication given through a vein that helps the immune system recognize and attack cancer cells. In this study it is used after surgery as part of the standard treatment plan to try to keep the cancer from coming back.

  • Calcium folinate

    is a vitamin‑like substance given by infusion into a vein. It is used together with chemotherapy to protect normal cells and reduce side effects, helping the chemotherapy work better.

  • Docetaxel

    is a chemotherapy drug given by injection into a vein. It works by stopping cancer cells from dividing and growing. In this trial it is part of the standard chemotherapy regimen given after surgery.

  • Oxaliplatin

    is another chemotherapy drug that is infused into a vein. It damages the DNA of cancer cells, which makes it harder for them to grow. It is included in the standard post‑operative chemotherapy schedule.

  • Fluorouracil

    (often called 5‑FU) is a chemotherapy medication delivered by infusion. It interferes with the cancer cells’ ability to make DNA, slowing or stopping their growth. It is one of the drugs used in the standard chemotherapy regimen after surgery.

What is already known about the treatment

  • Durvalumab

    This medication is given as an intravenous infusion, typically 1500 mg per dose. It is an approved immune‑checkpoint inhibitor used in several cancers and is being studied for low‑risk gastroesophageal adenocarcinoma. It works by blocking the PD‑L1 protein, allowing the body’s immune cells to recognize and attack tumor cells. It belongs to the class of monoclonal antibodies that target PD‑L1.

  • Calcium folinate

    Calcium folinate is administered by intravenous infusion at about 200 mg/m². It is a well‑known rescue agent used together with chemotherapy to lower side‑effects, especially with fluorouracil. The drug supplies a reduced form of folate that helps normal cells make DNA and protects them from damage. It is classified as a folate analog and a cytoprotective agent.

  • Docetaxel

    Docetaxel is given as an intravenous injection, usually 50 mg/m². It is a standard chemotherapy drug for many solid tumors and is part of the FLOT regimen for gastric cancer. The drug binds to tubulin proteins, preventing cancer cells from dividing properly. It is classified as a taxane, which is an antimitotic chemotherapy agent.

  • Oxaliplatin

    Oxaliplatin is delivered by intravenous infusion, typically 85 mg/m². It is a platinum‑based chemotherapy used in gastrointestinal cancers, including the FLOT protocol for gastric cancer. The drug creates cross‑links in DNA, stopping the tumor cells from copying their genetic material. It belongs to the class of platinum compounds, a type of alkylating‑like agent.

  • Fluorouracil

    Fluorouracil is given as an intravenous infusion, commonly 2600 mg/m². It is a widely used chemotherapy for many cancers, such as gastroesophageal adenocarcinoma. The medication mimics the natural building block uracil and interferes with DNA synthesis, which hinders cancer cell growth. It is classified as an antimetabolite and a pyrimidine analog.

Investigated diseases

Non‑metastatic gastric or gastroesophageal junction adenocarcinoma - It is a cancer that starts in the lining of the stomach or the area where the esophagus meets the stomach. The tumor grows outward and can invade nearby tissues such as the stomach wall and surrounding organs. Over time, cancer cells may spread locally within the abdomen. If the disease remains non‑metastatic, it has not yet reached distant organs. The condition typically develops slowly but can become more extensive if not controlled.
Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527239-32-00Protocol codeET26-200Estimated enrolment180 patientsSponsorCentre Leon Berard

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.